Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Marrow Irradiation with Melphalan for Multiple Myeloma
NCT02043860Phase 1Terminated
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2014
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Illinois Chicago. Primary endpoints: Progression Free Survival at 1 year and Maximum Tolerated Dose. Started Jan 2014; status: terminated.
Beyond the preview
Go deeper on NCT02043860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043860.